Business Context and Reporting Period
This Form 8-K is filed by BioSig Technologies, Inc. (not Streamex Corp.) on November 30, 2022. The report addresses the termination of a material definitive agreement regarding an at-the-market (ATM) equity offering.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to the equity offering capacity:
- Remaining ATM Capacity: Approximately $7.8 million in shares of Common Stock remained available for sale under the terminated agreement.
- Termination Penalties: None.
Material Changes
The primary material change is the termination of the ATM Sales Agreement entered into on May 17, 2022, with Virtu Americas LLC. The Company delivered written notice on November 30, 2022, making the termination effective December 1, 2022. This action halts the ability to issue up to $10 million of common stock through this specific agent.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the cessation of the ATM facility. The termination was executed pursuant to Section 13(b) of the Sales Agreement without incurring penalties.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Streamex Corp.) and the actual registrant (BioSig Technologies, Inc.).
- Confirm the effective date of the ATM termination (December 1, 2022) and its impact on current capital raising strategies.
- Review the original May 17, 2022, Form 8-K (Exhibit 1.1) for full terms of the terminated Sales Agreement.
- Check subsequent filings for any new equity financing arrangements to replace the terminated ATM facility.